NCT04414761View on ClinicalTrials.gov

Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response

PHASE3CompletedINTERVENTIONAL
Enrollment

784

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

October 10, 2022

Study Completion Date

October 10, 2022

Conditions
IVFGnRH AntagonistPPOS
Interventions
DRUG

Progesterone

oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger

DRUG

GnRH Antagonist

GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger

Trial Locations (1)

Unknown

ShangHai JIAI Genetics&IVF Institute, Shanghai

All Listed Sponsors
lead

ShangHai Ji Ai Genetics & IVF Institute

OTHER

NCT04414761 - Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response | Biotech Hunter | Biotech Hunter